CAB Spotlight - Vijaya Jori | Johns Hopkins University Baltimore-India Clinical Trials Unit

CAB Spotlight - Vijaya Jori

Date: 04/01/2022

Community Advisory Boards are key members of research programs. The ACTG Newsletter features Vijaya Jori of the JHU-BJGMC CAB!

Purpose: The C-TRIUMPH study has identified 20 household contacts (HHC), who have progressed to active TB from its HHCs cohort...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

TB is a major cause of illness and death in women of reproductive age. Pregnant and postpartum women with latent TB are at...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...